A phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (Bortezomib, Velcade), in patients with advanced cancer

Grace K. Dy, James P. Thomas, George Wilding, Laura Bruzek, Sumithra Mandrekar, Charles Erlichman, Dona Alberti, Kim Binger, Henry C. Pitot, Steven R. Alberts, Lorelei J. Hanson, Rebecca Marnocha, Kendra Tutsch, Scott H. Kaufmann, Alex A. Adjei

Research output: Contribution to journal › Article › peer-review

63 Scopus citations

Fingerprint

Dive into the research topics of 'A phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (Bortezomib, Velcade), in patients with advanced cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences